Merkel cell cancer medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 25: Line 25:


=== '''Adjuvant immunotherapy''' ===
=== '''Adjuvant immunotherapy''' ===
* Using monoclonal antibodies in patients with merkel cell cancer shows promising results especially if the patients have metastasis.  
* Using monoclonal antibodies in patients with merkel cell cancer shows promising results especially if the patients have metastasis.<ref name="pmid27592805">{{cite journal |vauthors=Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P |title=Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial |journal=Lancet Oncol. |volume=17 |issue=10 |pages=1374–1385 |date=October 2016 |pmid=27592805 |pmc=5587154 |doi=10.1016/S1470-2045(16)30364-3 |url=}}</ref>
* Preferred regimen (1):  Avelumab
* Preferred regimen (1):  Avelumab
* Preferred regimen (2): Nivolumab  
* Preferred regimen (2): Nivolumab  

Revision as of 00:56, 23 January 2019

Merkel cell cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Merkel Cell Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Merkel cell cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Merkel cell cancer medical therapy

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Merkel cell cancer medical therapy

CDC on Merkel cell cancer medical therapy

Merkel cell cancer medical therapy in the news

Blogs on Merkel cell cancer medical therapy

Directions to Hospitals Treating Merkel cell cancer

Risk calculators and risk factors for Merkel cell cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

The predominant therapy for Merkel cell cancer is surgical resection. Adjunctive chemoradiation may also be required in more advanced disease.

Medical Therapy

  • Merkel cell cancer that has metastasized may respond, at least partially, to treatment with chemotherapy and/or radiation.

Radiation

  • Radiation is an alternative treatment and used can be alone in patients with merkel cell cancer who are not suitable for surgery.[1]
  • Radiotherapy has a curative rate of 75 to 85 percent.[2]
  • Systemic relapse after radiotherapy is one f the cause of death in patients with merkel cell cancer.[3]

Chemotherapy or chemoradiotherapy

  • Patients with merkel cell carcinoma who are having a metastatic disease may get beneficial results with chemotherapy.[4]
  • Chemotherapy usually does not cure the disease, but it can be effective in shrinking the tumor size if the tumor is either too large to be resectable or is located within in critical or difficult regions.
  • Contraindications in using chemotherapy is immunosuppression which are of a great concern.
    • Preferred regimen (1): Carboplatin a weekly regimen IV: Target AUC 4.5 on day 1 of weeks 1, 4, 7, and 10
    • Preferred regimen (2): Etoposide IV concentrations >0.4 mg/mL

Adjuvant immunotherapy

  • Using monoclonal antibodies in patients with merkel cell cancer shows promising results especially if the patients have metastasis.[5]
  • Preferred regimen (1): Avelumab
  • Preferred regimen (2): Nivolumab
  • Preferred regimen (3): Pembrolizumab

References

  1. Pape E, Rezvoy N, Penel N, Salleron J, Martinot V, Guerreschi P, Dziwniel V, Darras S, Mirabel X, Mortier L (November 2011). "Radiotherapy alone for Merkel cell carcinoma: a comparative and retrospective study of 25 patients". J. Am. Acad. Dermatol. 65 (5): 983–90. doi:10.1016/j.jaad.2010.07.043. PMID 21641081.
  2. Harrington C, Kwan W (October 2014). "Outcomes of Merkel cell carcinoma treated with radiotherapy without radical surgical excision". Ann. Surg. Oncol. 21 (11): 3401–5. doi:10.1245/s10434-014-3757-8. PMID 25001091.
  3. Veness M, Foote M, Gebski V, Poulsen M (November 2010). "The role of radiotherapy alone in patients with merkel cell carcinoma: reporting the Australian experience of 43 patients". Int. J. Radiat. Oncol. Biol. Phys. 78 (3): 703–9. doi:10.1016/j.ijrobp.2009.08.011. PMID 19939581.
  4. Poulsen MG, Rischin D, Porter I, Walpole E, Harvey J, Hamilton C, Keller J, Tripcony L (January 2006). "Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?". Int. J. Radiat. Oncol. Biol. Phys. 64 (1): 114–9. doi:10.1016/j.ijrobp.2005.04.042. PMID 16125873.
  5. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P (October 2016). "Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial". Lancet Oncol. 17 (10): 1374–1385. doi:10.1016/S1470-2045(16)30364-3. PMC 5587154. PMID 27592805.


Template:WikiDoc Sources